<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02306629</url>
  </required_header>
  <id_info>
    <org_study_id>SL0032</org_study_id>
    <secondary_id>2014-000911-15</secondary_id>
    <nct_id>NCT02306629</nct_id>
  </id_info>
  <brief_title>Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood</brief_title>
  <official_title>An Open-label, Parallel-group, Single-dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Subcutaneous Epratuzumab in Healthy Caucasian and Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ACM Global Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eurofins Pharma Bioanalysis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Doctors Laboratory</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess how the absolute bioavailability, dose proportionality, pharmacokinetics, safety
      and tolerability of epratuzumab compared when given as a subcutaneous (sc) injection as to
      when given as an intravenous (iv) infusion in Caucasian and Japanese healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from Baseline to time of last detectable concentration (AUC(0-t))</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero up to infinity (AUC(0-inf))</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute bioavailability of the tested single sc doses</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of observed Cmax (tmax)</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t½)</measure>
    <time_frame>From Baseline (Day 1 pre-dose) to Day 85 (End of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Epratuzumab dose 1 sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab dose 2 sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab dose 3 sc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epratuzumab dose 2 iv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epratuzumab sc</intervention_name>
    <description>Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,</description>
    <arm_group_label>Epratuzumab dose 1 sc</arm_group_label>
    <arm_group_label>Epratuzumab dose 2 sc</arm_group_label>
    <arm_group_label>Epratuzumab dose 3 sc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epratuzumab iv</intervention_name>
    <description>Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,</description>
    <arm_group_label>Epratuzumab dose 2 iv</arm_group_label>
    <other_name>CDP3194</other_name>
    <other_name>EMAB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is male or female.

          -  At the Screening Visit, subject is 18 years to 50 years, inclusive (for Caucasian
             subjects), or 20 years to 50 years (for Japanese subjects)

          -  Subject must be in good health (physically and mentally) as determined by the
             investigator on the basis of medical history

          -  Subject has a body weight of 45 kg to 90 kg, inclusive, and body mass index (BMI)
             between 18.0 kg/m2 and 29.9 kg/m2, inclusive

          -  Japanese subjects are defined as a person carrying a Japanese passport, who is a
             descendant of 4 Japanese grandparents and has not been outside Japan for more than 5
             years prior to screening

          -  Females of childbearing potential are required to have a negative serum pregnancy test
             at the Screening Visit and must agree to use an acceptable method of birth control
             during the study and for a period of 3 months after the administration of
             investigational medicinal product (IMP)

          -  Male subjects must agree to use an acceptable method of contraception during the study
             and for at least 3 months after receiving IMP unless they have undergone vasectomy

        Exclusion Criteria:

          -  Subject has donated blood (including through participation in another clinical study)
             or suffered blood loss (≥450 mL) &lt;60 days prior to dosing, or has donated platelets
             &lt;14 days prior to dosing

          -  Subject has active malignancies or a history of malignancy

          -  Subject has a history of severe or multiple allergies

          -  Subject has a history of chronic infection, recent serious or life-threatening
             infection

          -  Subject with a recurrent history or active systemic/respiratory infection due to
             fungal, parasitic, or mycotic pathogens

          -  Subject has a positive HBsAg, anti-HCV or anti-HIV test result during the Screening
             Period

          -  Subject has a history of or a concurrent clinically significant illness, medical
             condition, or laboratory abnormality that, in the investigator's opinion, could affect
             the safety of the subject upon exposure to epratuzumab or confound the results of the
             study

          -  Female subjects who are breast feeding, pregnant, or plan to become pregnant during
             the study or within 3 months following dosing of the IMP

          -  Subjects who are immunocompromised

          -  A confirmed positive urine drug screen

          -  Subject has a history of substance abuse, drug addiction, or alcoholism within 3 years
             prior to study admission

          -  Subject is unable or unwilling to stop smoking during the inpatient stay

          -  Subject has previous exposure to, or has participated in studies with, any other
             anti-B-cell therapies

          -  Subject has a medical condition that requires chronic medication

          -  Subject has received a live vaccine in the month prior to the administration of IMP or
             is scheduled or expected to receive live vaccines during the study period or for 3
             months after administration of the IMP
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>01</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2014</study_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic Lupus Erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

